Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 9/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305112 | 1.00 | L3MBTL1 (0.42) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL4310477 | 1.00 | L3MBTL1 (0.42) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL1418909 | 1.00 | L3MBTL1 (0.42) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL511011 | 0.90 | ESR1 (0.40) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL511726 | 0.90 | ESR1 (0.40) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL511010 | 0.90 | ESR1 (0.40) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL1418591 | 0.90 | ESR1 (0.40) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL512238 | 0.89 | L3MBTL1 (0.43) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL512304 | 0.89 | L3MBTL1 (0.43) | L3MBTL1ESR1ARESR2SHBG | |
| SCHEMBL512239 | 0.89 | L3MBTL1 (0.43) | L3MBTL1ESR1ARESR2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HARBOR BIOSCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7935839-B2 | Sepsis treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2298315-A1 | Therapeutic treatment methods | Harbor BioSciences, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298316-A1 | Therapeutic treatment methods | Harbor BioSciences, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070265236-A1 | Asthma Treatment Methods | BIOVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070213309-A1 | Sepsis Treatment Methods | BIOVIE INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070203107-A1 | Pharmaceutical compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | L3MBTL1 3940/4885ESR1 220/4885AR 262/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | L3MBTL1 3940/4885ESR1 220/4885AR 262/4885 |
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 4429/4885ESR1 232/4885AR 440/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 3982/4885ESR1 154/4885AR 111/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 3950/4885ESR1 200/4885AR 117/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 3911/4885ESR1 192/4885AR 115/4885 |
| US-20070265236-A1 | Asthma Treatment Methods | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 3996/4885ESR1 216/4885AR 331/4885 |
| US-20050101581-A1 | Therapeutic treatment methods 2 | HSD3B2, HSD3B1, HSD17B2 | L3MBTL1 3929/4885ESR1 259/4885AR 379/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | L3MBTL1 3626/4885ESR1 354/4885AR 392/4885 |
| US-20070213309-A1 | Sepsis Treatment Methods | HSD3B1, ELANE, HSD3B2 | L3MBTL1 3108/4885ESR1 114/4885AR 665/4885 |
| US-20070203107-A1 | Pharmaceutical compositions | HSD3B1, HSD3B2, HSD17B13 | L3MBTL1 4665/4885ESR1 246/4885AR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.